Literature DB >> 17084198

Rising incidence of primary central nervous system lymphoma in Kumamoto, Japan.

Keishi Makino1, Hideo Nakamura, Takeshi Kino, Hideo Takeshima, Jun-Ichi Kuratsu.   

Abstract

BACKGROUND: Primary central nervous system lymphoma is an extranodal form of non-Hodgkin lymphoma arising in the craniospinal axis. The incidence of PCNSL is reportedly on the increase in some parts of the world in the last 2 decades.
METHODS: We surveyed 4007 patients diagnosed with PIT between 1989 and 2004, with histologic diagnosis being obtained in 70% of the patients. Of these, the PCNSL cases were reviewed.
RESULTS: Of 4007, 136 (3.4%) carried a diagnosis of PCNSL. At 0.41 per 100,000 per year, the age-adjusted incidence rate for that period was higher than that for the period from 1989 to 1998 (0.29 per 100,000 per year). Moreover, the number of patients with PCNSL doubled from 45 (1989-1996) to 91 (1997-2004).
CONCLUSIONS: Our findings point to an increase in the incidence of PCNSL among immunocompetent individuals in Kumamoto Prefecture.

Entities:  

Mesh:

Year:  2006        PMID: 17084198     DOI: 10.1016/j.surneu.2006.05.055

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  10 in total

1.  High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study.

Authors:  E Schorb; C P Fox; K Fritsch; L Isbell; A Neubauer; A Tzalavras; R Witherall; S Choquet; O Kuittinen; D De-Silva; K Cwynarski; C Houillier; K Hoang-Xuan; V Touitou; N Cassoux; J-P Marolleau; J Tamburini; R Houot; V Delwail; G Illerhaus; C Soussain; B Kasenda
Journal:  Bone Marrow Transplant       Date:  2017-04-24       Impact factor: 5.483

Review 2.  First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.

Authors:  B Kasenda; A J M Ferreri; E Marturano; D Forst; J Bromberg; H Ghesquieres; C Ferlay; J Y Blay; K Hoang-Xuan; E J Pulczynski; A Fosså; Y Okoshi; S Chiba; K Fritsch; A Omuro; B P O'Neill; O Bairey; S Schandelmaier; V Gloy; N Bhatnagar; S Haug; S Rahner; T T Batchelor; G Illerhaus; M Briel
Journal:  Ann Oncol       Date:  2015-02-20       Impact factor: 32.976

3.  Inhibition of eIF4E phosphorylation reduces cell growth and proliferation in primary central nervous system lymphoma cells.

Authors:  Daisuke Muta; Keishi Makino; Hideo Nakamura; Shigetoshi Yano; Mareina Kudo; Jun-Ichi Kuratsu
Journal:  J Neurooncol       Date:  2010-05-25       Impact factor: 4.130

4.  Epidemiological study of primary intracranial tumors: a regional survey in Kumamoto prefecture in southern Japan--20-year study.

Authors:  Hideo Nakamura; Keishi Makino; Shigetoshi Yano; Jun-Ichi Kuratsu
Journal:  Int J Clin Oncol       Date:  2011-01-18       Impact factor: 3.402

5.  Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma.

Authors:  Vaios Hatzoglou; Jung Hun Oh; Olivia Buck; Xuling Lin; Michelle Lee; Amita Shukla-Dave; Robert J Young; Kyung K Peck; Behroze Vachha; Andrei I Holodny; Christian Grommes
Journal:  J Neurooncol       Date:  2018-08-02       Impact factor: 4.130

Review 6.  Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment.

Authors:  James Rubenstein; Andrés J M Ferreri; Stefania Pittaluga
Journal:  Leuk Lymphoma       Date:  2008

7.  Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation.

Authors:  Elisabeth Schorb; Benjamin Kasenda; Johannes Atta; Stephan Kaun; Anke Morgner; Georg Hess; Thomas Elter; Nikolas von Bubnoff; Martin Dreyling; Mark Ringhoffer; Stefan W Krause; Günter Derigs; Beate Klimm; D Niemann; Kristina Fritsch; Jürgen Finke; Gerald Illerhaus
Journal:  Haematologica       Date:  2013-01-08       Impact factor: 9.941

8.  Changing Incidence and Survival of Primary Central Nervous System Lymphoma in Australia: A 33-Year National Population-Based Study.

Authors:  Alexandra L Farrall; Justine R Smith
Journal:  Cancers (Basel)       Date:  2021-01-22       Impact factor: 6.639

9.  An Unusual Case of EBV-Negative Primary CNS Lymphoma of Natural Killer/T-Cell Lineage.

Authors:  Naim I Kajtazi; Mohammed Bafaquh; Juman Al Ghamdi; Zahra AlEissa; Arwa Al Shmeikh; Ali Alsaeed; Tarek Sulaiman; M Adelita Vizcaino; Majed Al Hameed; Aditya Raghunathan
Journal:  Clin Pathol       Date:  2021-12-12

10.  Curative effect of methotrexate combined with teniposide in the treatment of primary central nervous system lymphoma.

Authors:  Yi-Xia Wang; Yan Huang; Xiao-Ping Xu; Bo-Bin Chen; Zhi-Guang Lin; Yan Ma; Tian-Ling Ding; Qian Wang
Journal:  Oncol Lett       Date:  2020-01-22       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.